Singlera Genomics
A developer of 'liquid biopsy' analysis reagents and software, focusing on determing methylation haplotypes across many thousands of genomic locations in cell-free DNA.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
* | CNY100m | Late VC | |
| Total Funding | 000k | ||
Related Content
Singlera Genomics is a company that specializes in liquid biopsy for non-invasive early cancer detection. The company has developed proprietary technologies for analyzing cell-free DNA (cfDNA) methylation, which allows for the early detection of various types of cancer.
Their product portfolio includes assays for different cancers, such as the PDACatch for pancreatic cancer, which has received Breakthrough Device Designation from the FDA, and ColonAiQ for colorectal cancer, which has been approved by the NMPA in China. The company's business model revolves around the development and commercialization of these diagnostic tests. They serve high-risk individuals and the broader healthcare market, providing tools for cancer screening, diagnosis, and monitoring. Singlera Genomics operates globally with locations in the US and China and generates revenue through the sale of its diagnostic products and services.
Keywords: liquid biopsy, cancer diagnostics, genomics, cfDNA, methylation, oncology, early detection, non-invasive, molecular diagnostics, precision medicine